Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications
Completed
Novartis Pharmaceuticals
Phase 3
2002-01-01
This study is a test of the safety and effectiveness of two drugs, one for diabetes and one
for hypertension, in keeping patients with high lab values of glucose from progressing to
frank diabetes and developing cardiovascular complications. People in this study cannot have
frank diabetes but are considered "borderline" based on blood tests. People in the study take
none, one or both of the drugs and do not know which one(s) they are taking.
Nateglinide: a Double Blind Add-on Study With Pioglitazone for Type 2 Diabetic Patients
Completed
Ajinomoto USA, INC.
Phase 2/Phase 3
1969-12-31
The purpose of this study is to investigate the superiority of nateglinide over placebo for
inadequately controlled type 2 diabetic patients with pioglitazone treatment.
Nateglinide: a Double Blind Add-on Study With Pioglitazone for Type 2 Diabetic Patients
Completed
Astellas Pharma Inc
Phase 2/Phase 3
1969-12-31
The purpose of this study is to investigate the superiority of nateglinide over placebo for
inadequately controlled type 2 diabetic patients with pioglitazone treatment.
Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes
Completed
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase 4
2002-11-01
The purpose of this study is to examine the effects of treating insulin resistance on memory
and attention, brain glucose utilization, and proteins in spinal fluid.
A Pilot Study to Evaluate the Effects of Nateglinide vs. Glibenclamide on Renal Hemodynamics and Albumin Excretion
Completed
Novartis Pharmaceuticals
Phase 4
2003-05-01
This study is not being conducted in the United States. The purpose of the study is to
evaluate the effects of nateglinide compared to glibenclamide on renal hemodynamics and
albumin excretion.
Insulin Resistance and Vessel Function After Meals: Does Early Intervention Make a Difference?
Completed
Bayer
Phase 4
2003-06-01
The purpose of this study is to determine whether attenuation/normalization of elevated blood
sugar after meals ameliorates vessel wall (endothelial) function in individuals with insulin
resistance.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
